The results of our study demonstrated that PXR expression, assessed immunohistochemically in histopathological samples of breast carcinoma patients, was correlated with crucial clinicopathological parameters for patients’ management and prognosis. This evidence concerns the gene NR1I2 and breast carcinoma.